28.09.2012 - German university hospital Charité and French pharma company Sanofi have agreed to expand their joint research efforts to the field of diabetes.
The partnership of the Charité and Sanofi had begun in summer 2010, initially with a focus in the field of stroke research. Following a decision on 27 September, scientists and clinicians from both sides will now work together in the field of diabetes research as well. The goal is to better understand the medical needs of patients and to find new targeted approaches to cure or treat the disease.
The partners have already agreed on a first target molecule to investigate further. Researchers from Charité discovered the yet undisclosed molecule, which will now fuel a core project at the newly founded Sanofi-Charité-diabetic laboratory. The target molecule seems to be promising, as results from laboratory tests indicate that it inhibition might protect the body from diet-and age-induced obesity and insulin resistance. “With Charité we have built a highly efficient scientific cooperation over the past two years,” said Jochen Maas, Director of Research and Development of Sanofi-Aventis Deutschland GmbH and head of the German research and development center of Sanofi.
Karl Max Einhäupl, CEO of the Charité, welcomed the enhanced cooperation as well: “Diabetes is a major challenge for our health system. Bringing together the clinical experience and the academic performance of physicians and scientists of the Charité with the development and application expertise of Sanofi, will generate valuable inputs for the development of successful diabetes therapies.”
17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more